5 Key Takeaways

• 1

  Hoth Therapeutics is utilizing AI to advance its investigational targeted therapy HT-KIT for KIT-driven cancers.

• 2

  The AI platform aids in data analysis, cancer pathway modeling, and regulatory documentation for IND submission.

• 3

  HT-KIT targets rare cancers driven by KIT mutations, including systemic mastocytosis and gastrointestinal stromal tumors.

• 4

  Preclinical studies show HT-KIT achieved over 80% reduction in KIT mRNA and protein expression in cancer models.

• 5

  Safety data from preclinical studies indicate no dose-limiting toxicities, supporting the candidate's progression to phase I.